KFA115

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

KFA115 is an experimental drug being studied by Novartis Pharmaceuticals. It is currently in Phase 1 clinical trials for various advanced cancers, including colorectal cancer. These early-stage trials are primarily focused on determining the safest dose and how patients tolerate the drug, both when given alone and in combination with another immunotherapy drug called pembrolizumab. The trials are looking at patients with specific characteristics, such as BRAF mutations, MSI-H status, PD-L1 expression levels, or VEGF mutations. The goal is to see if KFA115 has any early signs of effectiveness (anti-tumor activity) in these patient groups. KFA115 is not yet approved for treating colorectal cancer or any other condition.

Mechanism of Action

KFA115 is being investigated as a potential treatment for certain advanced cancers. The specific way it works (its mechanism of action) is still being studied in clinical trials. It is being tested both by itself and in combination with pembrolizumab, an immunotherapy drug that helps the immune system fight cancer. The trials aim to understand how KFA115 affects the cancer and how it interacts with the immune system.

Side Effects

Because KFA115 is an experimental drug in early-phase clinical trials (Phase 1) The full range of potential side effects is still being evaluated. The primary focus of Phase 1 trials is to assess safety and tolerability. Information about specific side effects experienced by patients in these trials is typically not widely released until later phases or after drug approval. Patients participating in these trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT05544929 Phase 1
Active, not recruiting
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
United States, Canada, China, France, Germany, Hong Kong, Italy, Japan, Singapor

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.